Program
pertuzumab
Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.
Drug pagePertuzumab: every studyMany companies study it; this page follows only the 46 they lead. All 156 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 411 open or running | phase 4since May 13, 2015 | Nov 15, 2001 | Mar 28, 2027phase 3 · NCT02320435 |
| Cinnagenits history only | 10 open or running | phase 3since Jun 22, 2021 | Jun 22, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Nov 25, 2022 | Nov 25, 2022 | none ahead |
| Mabscale | 11 open or running | phase 1since Apr 11, 2023 | Apr 11, 2023 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Aug 27, 2014 | Aug 27, 2014 | none ahead |
| Zydus Lifesciencesits history only | 10 open or running | phase 3since Feb 26, 2022 | Feb 26, 2022 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mabscale only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 25, 2022Named pertuzumabINNProposed as its International Nonproprietary Name in WHO's List 126
- Apr 11, 2023First study: phase 1 study in Healthy MenFirst studyNCT05825781 · 114 enrolled · Russian Federation
TargetBeta
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The one study Mabscale leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05825781Healthy Men · Russian Federation | 1 | Active, not recruiting | Jan 22, 2024 | 114 |
How it is read
Names in the registry
- “Pertuzumab”, 36 entries
- “Pertuzumab IV”, 4 entries
- “Perjeta”, 3 entries
- “pertuzumab”, 2 entries
- “RhuMab 2C4”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 34 studies
- Ovarian Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Stomach Neoplasms, 2 studies
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.